Enhanced immune evasion of SARS-CoV-2 variants KP.3.1.1 and XEC through N-terminal domain mutations

Jingyi Liu¹, Yuanling Yu², Fanchong Jian³, Sijie Yang⁴, Weiliang Song⁵, Peng Wang², Lingling Yu², Fei Shao⁵, Yunlong Cao⁶

Affiliations

¹ Biomedical Pioneering Innovation Center, Peking University, Beijing 100871, China; College of Future Technology, Peking University, Beijing 100871, China; Changping Laboratory, Beijing, China.
² Changping Laboratory, Beijing, China.
³ Biomedical Pioneering Innovation Center, Peking University, Beijing 100871, China; College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, China; Changping Laboratory, Beijing, China.
⁴ Biomedical Pioneering Innovation Center, Peking University, Beijing 100871, China; Changping Laboratory, Beijing, China; Peking-Tsinghua Center for Life Sciences, Tsinghua University, Beijing, China.
⁵ Biomedical Pioneering Innovation Center, Peking University, Beijing 100871, China; School of Life Sciences, Peking University, Beijing 100871, China; Changping Laboratory, Beijing, China.
⁶ Biomedical Pioneering Innovation Center, Peking University, Beijing 100871, China; School of Life Sciences, Peking University, Beijing 100871, China; Changping Laboratory, Beijing, China. Electronic address: yunlongcao@pku.edu.cn.

PMID: 39586310
DOI: 10.1016/S1473-3099(24)00738-2

Enhanced immune evasion of SARS-CoV-2 variants KP.3.1.1 and XEC through N-terminal domain mutations

Jingyi Liu et al. Lancet Infect Dis. 2025 Jan.

. 2025 Jan;25(1):e6-e7.

doi: 10.1016/S1473-3099(24)00738-2. Epub 2024 Nov 22.

Authors

Jingyi Liu¹, Yuanling Yu², Fanchong Jian³, Sijie Yang⁴, Weiliang Song⁵, Peng Wang², Lingling Yu², Fei Shao⁵, Yunlong Cao⁶

Affiliations

¹ Biomedical Pioneering Innovation Center, Peking University, Beijing 100871, China; College of Future Technology, Peking University, Beijing 100871, China; Changping Laboratory, Beijing, China.
² Changping Laboratory, Beijing, China.
³ Biomedical Pioneering Innovation Center, Peking University, Beijing 100871, China; College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, China; Changping Laboratory, Beijing, China.
⁴ Biomedical Pioneering Innovation Center, Peking University, Beijing 100871, China; Changping Laboratory, Beijing, China; Peking-Tsinghua Center for Life Sciences, Tsinghua University, Beijing, China.
⁵ Biomedical Pioneering Innovation Center, Peking University, Beijing 100871, China; School of Life Sciences, Peking University, Beijing 100871, China; Changping Laboratory, Beijing, China.
⁶ Biomedical Pioneering Innovation Center, Peking University, Beijing 100871, China; School of Life Sciences, Peking University, Beijing 100871, China; Changping Laboratory, Beijing, China. Electronic address: yunlongcao@pku.edu.cn.

PMID: 39586310
DOI: 10.1016/S1473-3099(24)00738-2

No abstract available

PubMed Disclaimer

Conflict of interest statement

JL and YY contributed equally. YC has provisional patent applications for the BD series antibodies (WO2024131775A9 and WO2023151312A1), and is the founder of Singlomics Biopharmaceuticals. All other authors declare no competing interests.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Enhanced immune evasion of SARS-CoV-2 variants KP.3.1.1 and XEC through N-terminal domain mutations

Affiliations

Enhanced immune evasion of SARS-CoV-2 variants KP.3.1.1 and XEC through N-terminal domain mutations

Authors

Affiliations

Conflict of interest statement

Publication types

LinkOut - more resources

Full Text Sources

Miscellaneous